Andreas Tiede/ResearchGate
Dec 8, 2025, 11:08
Andreas Tiede: This Will Change Hematology Forever
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared on LinkedIn:
”This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025”
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
More from ASH25 featured in Hemostasis Today.
-
Feb 12, 2026, 16:36Tagreed Alkaltham: Tranexamic Acid in PBM
-
Feb 12, 2026, 16:35Paul Lambis Announces Maria Hadjidemetriou as a Speaker at Cyprus Diaspora Forum
-
Feb 12, 2026, 16:34Rahul Bhargava: Breaking Myths About Bone Marrow Transplant
-
Feb 12, 2026, 16:29Arun V J: Can You Be A Doctor And Still Be Stupid?
-
Feb 12, 2026, 16:26Changing the Narrative Around PPH – End Postpartum Hemorrhage
-
Feb 12, 2026, 16:20Mahesan Subramaniam: The Protective Switch in Brain Immune Cells Could Slow Alzheimer’s Disease
-
Feb 12, 2026, 16:13Lale Tokgözoğlu: Top 10 Dyslipidemia Papers of 2025
-
Feb 12, 2026, 16:10Neelam Mohan: Breaking Down Anemia from Causes and Testing to Treatment and Prevention
-
Feb 12, 2026, 16:04Irma Bagdoniene: From Estimating Risk to Seeing Disease in Preventive Cardiology